FIELD: medicine.
SUBSTANCE: method involves sucking 45-55% of circulating blood volume. The blood loss is compensated with Ringer solution and following thromboplastin solution introduction at a dose of 16-20 mg/kg of rat body mass.
EFFECT: high reality degree in reproducing acute lung injury state.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR STIMULATING ACUTE PULMONARY INJURY | 2010 |
|
RU2456677C2 |
| METHOD FOR SIMULATION AND PHARMACEUTICAL CORRECTION OF ACUTE PULMONARY INJURY EXPERIMENTALLY | 2013 |
|
RU2541831C2 |
| APPLICATION OF AN ALPHA1-PROTEINASE INHIBITOR (ALPHA1-ANTITRYPSIN) FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND METHOD FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME USING ALPHA1-ANTITRYPSIN | 2020 |
|
RU2757875C1 |
| USE OF ENISAMIUM IODIDE FOR THE PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | 2022 |
|
RU2799328C1 |
| METHOD FOR THE PREVENTION OR THERAPY OF ACUTE RESPIRATORY DISTRESS SYNDROME USING A MODEL OF INDUCED ARDS IN LABORATORY ANIMALS | 2021 |
|
RU2772735C1 |
| PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY ACTION | 2022 |
|
RU2801579C1 |
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| METHOD OF MODELING HEMOSTASIS DISORDERS IN COMBINED LUNG LESIONS WITH BACTERIAL INFLAMMATION AND PULMONARY VASCULAR THROMBOSIS | 2023 |
|
RU2800645C1 |
| MEDICINAL PRODUCT WITH ANTICOAGULANT (INHIBITOR OF FACTOR IIA), ANTITHROMBOTIC, ANTI-INFLAMMATORY ACTIVITIES AND CONTAINING 5,7-DI(THIOPHEN-2-IL)-4,5-DIHYDRO-[1,2,4]TRIAZOLO[1,5-a ]PYRIMIDINE | 2022 |
|
RU2798587C1 |
| CHEMICAL COMPOUND TETRASUBSTITUTED WITH GLYCOLIC ACID PICEATANNOL (E)-2,2'-((4-(3,5-BIS(CARBOXYLATOMETHOXY)STYRYL)-1,2-PHENYLENE)BIS(OXY)) DIACETATE, PHARMACEUTICAL COMPOSITION AND ITS USE FOR TREATING SYSTEMIC INFLAMMATORY DISEASES AND CONDITIONS, INCLUDING ACUTE RESPIRATORY DISTRESS SYNDROME | 2023 |
|
RU2826492C1 |
